MacroGenics Clears Key FDA Hurdle, Sparking Analyst Optimism

MacroGenics' LINNET trial resumes after FDA lifts partial clinical hold on lorigerlimab. B. Riley upgrades stock to 'Buy' citing strong ADC pipeline and financial runway into 2027.

A major regulatory obstacle for MacroGenics has been removed. The U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the company's LINNET trial, allowing the study of its drug candidate lorigerlimab in ovarian cancer to proceed. This decision, confirmed this week, ends a two-month suspension that began in February 2026 after four participants experienced severe, life-threatening side effects.

The green light from regulators comes with revised safety protocols. MacroGenics plans to resume patient recruitment under an amended study design incorporating additional safety measures. To date, 41 of the originally planned 60 patients have undergone treatment with lorigerlimab, a bispecific antibody targeting the PD-1 and CTLA-4 checkpoints. The company has committed to providing a comprehensive program update by mid-2026.

Financial analysts reacted swiftly to the news. B. Riley upgraded MacroGenics stock from "Neutral" to "Buy" and dramatically increased its price target from $3 to $9 per share. The firm cited the company's strong positioning in the next-generation antibody-drug conjugate (ADC) market, particularly regarding ADAM9-directed therapies, as a key reason for the upgrade. They believe significant valuation potential remains untapped.

From a financial standpoint, MacroGenics appears well-equipped to navigate its upcoming clinical milestones. The company reported cash, cash equivalents, and marketable securities of approximately $189.9 million as of the end of fiscal year 2025. Management expects this capital reserve to fund operations into late 2027.

The path forward remains event-focused. Beyond the LINNET trial progress, MacroGenics anticipates data readouts for its MGC026 and MGC028 programs. Furthermore, the company is preparing to submit a new drug application for MGC030. These catalysts, concentrated in 2026, are seen as critical for validating the long-term potential of its oncology pipeline. The FDA's decision to lift the clinical hold prevents a major developmental delay and allows the company to advance its core research as planned.